T-cell/histiocyte rich large B cell lymphoma
MONDO:0017597T-cell/histiocyte rich large B cell lymphoma (THRLBCL) is a rare variant of diffuse large B-cell lymphoma (DLBCL), mainly affecting middle-aged men and often not being discovered until an advanced disease stage, with involvement of the spleen, liver and bone marrow occurring at a greater frequency than in DLBCL. It is often difficult to diagnose due to its similarity with other lymphoid diseases such as classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma and has an aggressive clinical course.
Also known as: T-cell rich/histiocyte-rich large B-cell lymphoma, T-cell/histiocyte rich lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, THRLBCL
2026 clinical trials for this condition and its sub-types, 31 tagged with T-cell/histiocyte rich large B cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR T-Cell therapy shows promise against tough lymphoma in major trial
Disease control CompletedThis phase 3 trial tested whether a personalized cell therapy called axicabtagene ciloleucel (Yescarta) works better than standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 359 participants and compared event-fre…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Spinal injection may shield brain from lymphoma spread
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC